Clinical trial · Interventional
MRI (Including Spectroscopy and Fat-Saturations and Diffusion-Weighted Imaging) in Cervical Cancer
A Study of Novel Magnetic Resonance Imaging Sequences for Target Delineation and Prognostication in Cervical Cancer
NCT01060033CI-TRIAL-00026985MRIcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To detect differences in MR spectroscopy, diffusion weighted MR, diffusion tensor imaging (DTI) or dynamic contrast enhancement (DCE) MR imaging between primary cervical tumors and normal cervical tissue.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uterine Cervical Neoplasms | Cervical Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diffusion Tensor Imaging (DTI) | Device | — | UNRESOLVED |
| Dynamic Contrast Enhancement MRI (MR-DCE) | Device | — | UNRESOLVED |
| Fat-Saturation and Diffusion-Weighted Imaging | Device | — | UNRESOLVED |
| MR Spectroscopy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Arm 1
- description
- * Clinical T1/T2-weighted MRI sequence per standard of care before treatment, during treatment per standard protocol, and at 3 months. * Patients may have one or all of the following sequences in addition to the standard MRI imaging: * MR Spectroscopy * Fat-saturation and Diffusion-Weighted Imaging * Dynamic Contrast Enhancement MRI (MR-DCE) * Diffusion Tensor Imaging (DTI)
- interventionNames
- Device: MR Spectroscopy
- Device: Fat-Saturation and Diffusion-Weighted Imaging
- Device: Dynamic Contrast Enhancement MRI (MR-DCE)
- Device: Diffusion Tensor Imaging (DTI)
Primary outcomes (1)
- measure
- Differences in MR spectroscopy, diffusion weighted MR, diffusion tensor imaging (DTI) or dynamic contrast enhancement (DCE) MR imaging between primary cervical tumors and normal cervical tissue.
- timeFrame
- 3 months
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must have biopsy-proven newly diagnosed squamous cell cervical cancer (FIGO clinical stages IB2-IVA). * Patients must be ≥ 18 years of age. * Patients must be able to receive standard radiation therapy (external beam radiation and brachytherapy) with or without chemotherapy. * Patients with distant metastatic disease are eligible provided the estimated survival of the patient is at least one year. * Patients must be scheduled to undergo or have already undergone FDG-PET/CT imaging for clinical staging cervical cancer at Barnes-Jewish Hospital Clinical PET facility on the Siemens Biograph 40 True Point Tomograph Scanner or elsewhere in the WUSM Nuclear Medicine department using the quality controls instituted by Nuclear Medicine. * Patients must be able to give informed consent. Exclusion Criteria: * Patients with another known active malignancy. * Patients who have received treatment for any malignancy (with the exception of non-melanoma skin cancer) in the past 5 years. * Pregnant or breastfeeding patients. * Patients whose tumors are not FDG avid on baseline standard of care FDG-PET/CT imaging. * Patients with contraindications to MRI scanning.
References
Publications (0)
Data not yet available
No reference posted for this study.